%0 Journal Article
%T A Randomized, Controlled Trial of Trifarotene Plus Doxycycline for Severe Acne Vulgaris.
%A Del Rosso JQ
%A Johnson SM
%A Schlesinger T
%A Green L
%A Sanchez N
%A Lain E
%A Draelos Z
%A York JP
%A Chavda R
%A Del Rosso JQ
%A Johnson SM
%A Schlesinger T
%A Green L
%A Sanchez N
%A Lain E
%A Draelos Z
%A York JP
%A Chavda R
%J J Clin Aesthet Dermatol
%V 15
%N 7
%D Jul 2022
%M 35942016
暂无%X <B>UNASSIGNED: </B>We evaluated the efficacy and safety of trifarotene plus oral doxycycline in acne.<BR><B>UNASSIGNED: </B>This was a randomized (2:1 ratio) 12-week, double-blind study of once-daily trifarotene cream 50µg/g plus enteric-coated doxycycline 120mg (T+D) versus trifarotene vehicle and doxycycline placebo (V+P). Patients were aged 12 years or older with severe facial acne (≥20 inflammatory lesions, 30 to 120 non-inflammatory lesions, and ≤4 nodules). Efficacy outcomes included change from baseline in lesion counts and success (score of 0/1 with ≥2 grade improvement) on investigator global assessment (IGA). Safety was assessed by adverse events and local tolerability.<BR><B>UNASSIGNED: </B>The study enrolled 133 subjects in the T+D group and 69 subjects in the V+P group. The population was balanced, with an approximately even ratio of adolescent (12-17 years) and adult (≥18 years) subjects. The absolute change in lesion counts from baseline were: -69.1 T+D versus -48.1 V+P for total lesions, -29.4 T+D versus -19.5 V+P for inflammatory lesions, and -39.5 T+D versus -28.2 for non-inflammatory lesions (P<0.0001 for all). Success was achieved by 31.7 percent of subjects in the T+D group versus 15.8 percent in the V+P group (P=0.0107). The safety and tolerability profiles were comparable between the T+D and V+P arms.<BR><B>UNASSIGNED: </B>T+D was demonstrated to be safe and efficacious as a treatment option for patients with severe acne.